Exelixis (EXEL) reported $598.66 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 5.6%. EPS of $0.94 for the same period compares to $0.55 a year ago.

Exelixis, Inc. (NASDAQ:EXEL) is one of the best healthcare stocks under $50 to invest in. On February 4, Barclays revised the price target on Exelixis, Inc. (NASDAQ:EXEL) to $44 from $41 and ...

Nick Van Exel's path to the NBA wasn't just about talent. It was about surviving the draft process, as well as there were about 14 team workouts scheduled back-to-back across the country, designed to ...

Sedrani previously led Exel’s establishment as a Merak Capital subsidiary and scaled its accelerator operations. He also serves as VP of innovation platform at Merak Capital, overseeing growth-focused ...

Riyadh, Saudi Arabia - Exel by Merak, a subsidiary of Merak Capital and Saudi Arabia’s premier innovation platform company, has concluded the Demo Day for its second gaming accelerator cohort, marking ...

RBC Capital analyst Leonid Timashev maintained a Hold rating on Exelixis yesterday and set a price target of $46.00. According to TipRanks, Timashev is a 5-star analyst with an average return of 19.0% ...